Search Results

South Korea's Daewoong Pharmaceutical Partners with Promedius to Promote AI Osteoporosis Screening Solution Using Chest X-rays

Daewoong Pharmaceutical announced on August 27 that it has signed a sales, distribution, and joint promotion agreement with Promedius, a medical imaging AI company, to promote Osteo Signal, an AI-based osteoporosis risk screening solution using chest X-rays, in South Korea. This partnership also marks Daewoong Pharmaceutical's expansion from its existing osteoporosis treatment business into the AI-assisted diagnostics field. Under the agreement, Daewoong Pharmaceutical will leverage its business network covering medical institutions across South Korea, along with its sales and marketing capabilities, to bring the solution into more clinical settings. Promedius will provide medical imaging AI technical support to assist in its deployment in real-world medical environments.

2026-08-27

Fujifilm Launches New X-ray Bone Densitometer for Early Osteoporosis Screening

Fujifilm Corporation announced on August 26 that it has begun selling a new X-ray bone densitometry device designed to measure bone density in areas such as the lumbar spine and femur, supporting early detection of osteoporosis and fracture risk assessment. According to the company, the X-ray bone densitometer measures bone density using X-rays and is an important diagnostic tool for osteoporosis. The newly launched model is Fujifilm's first new device of this kind since 2018 and will be sold through its subsidiary Fujifilm Medical, with a price of approximately 20 million yen, varying depending on system configuration. The new device incorporates artificial intelligence technology, enhancing automated analysis functions. In the analysis of scanned images...

2026-08-26

DXA Screening Among U.S. Medicare Population Declines 35% Over Nearly Two Decades

A new study shows that between 2005 and 2023, the rate of dual-energy X-ray absorptiometry (DXA) examinations among U.S. Medicare beneficiaries declined significantly, by 35%. DXA is commonly used for bone density testing and osteoporosis-related screening, and the findings suggest that disparities in screening access across different populations are widening. Researchers analyzed claims data from more than 5 million Medicare beneficiaries. The results showed that DXA utilization fell from 7,255 exams per 100,000 beneficiaries in 2005 to 4,690 per 100,000 beneficiaries in 2023. The study was published in Osteoporosis International. The decline was not uniform across populations...

2026-08-08